Learning Hub Central
Uncategorized
Locally Advanced Non-Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
Myelodysplastic Syndromes and Acute Myeloid Leukemia
Uncategorized
Non-CME Credit Course
How I Treat Acute Myeloid Leukemia
Uncategorized
Non-CME Credit Course
Small Cell Lung Cancer: Novel Approaches 2019
Uncategorized
Non-CME Credit Course
Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials
Uncategorized
Non-CME Credit Course
New Developments in Cancer Research Hepatocellular and Biliary Cancers
Uncategorized
Non-CME Credit Course
Combination Radiation and Immunotherapy
Uncategorized
Non-CME Credit Course
New Directions in the Management of Ovarian Cancer
Uncategorized
Non-CME Credit Course
Nasopharyngeal Carcinoma (NPC) 2019
Uncategorized
Non-CME Credit Course
Updates in Hormone-receptor Positive Breast Cancer
Uncategorized
Non-CME Credit Course
Soft Tissue Sarcomas
Uncategorized
Non-CME Credit Course
Phase I Trials: Whats New in 2019?
Uncategorized
Non-CME Credit Course
Triple Negative Breast Cancer/BRCA Mutated Breast Cancer: What's New?
Uncategorized
Non-CME Credit Course
CAR-T Cells and Other Cell Based Therapies
Uncategorized
Non-CME Credit Course
Handling Common Toxicities of Immune Checkpoint Inhibitors
Uncategorized
Non-CME Credit Course
Squamous Cell Carcinoma of the Lung: Finally Some Progress
Uncategorized
Non-CME Credit Course
ER/PR Breast Disease: Early Stage, Locally Advanced and Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
B-Cell NHL and Hodgkin’s Disease
Uncategorized
Non-CME Credit Course
RET- MET- and NTRK in Non-Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
CLL: At Recurrence- What is the Best Therapy and What is Coming from the Bench Lab?
Uncategorized
Non-CME Credit Course
The Entire Sepctrum of Her-2 Management in Breast Cancer Disease: All Clinical Settings
Uncategorized
Non-CME Credit Course
Managing Expectations – Goals of Care
Uncategorized
Non-CME Credit Course
The Role of Liquid Biopsy in Cancer Care: The Revolution
Uncategorized
Non-CME Credit Course
Upper GI Malignancies - Updates
Uncategorized
Non-CME Credit Course
Therapeutic Developments For Neuroendocrine Tumors of the GI Tract and Others
Uncategorized
Non-CME Credit Course
Challenges in Immunotherapy in NSCLC
Uncategorized
Non-CME Credit Course
Managing Toxicities from Commonly Used Agents in Colorectal Cancer (CRC)
Uncategorized
Non-CME Credit Course
CLL - How Do You Decide the Best Frontline Therapy
Uncategorized
Non-CME Credit Course
Cannabis and Cancer: Myths and Reality
Uncategorized
Non-CME Credit Course
HRPC - How to Sequence Multiple Therapies
Uncategorized
Non-CME Credit Course
Immunotherapy for Head and Neck Cancers
Uncategorized
Non-CME Credit Course
From Bench to Bedside (and Back): Early Clinical Trials
Uncategorized
Non-CME Credit Course
EGFR Mutations: What's Next?
Uncategorized
Non-CME Credit Course
Choosing Optimal Therapy for Relapsed Multiple Myeloma Patient
Uncategorized
Non-CME Credit Course
Myelodysplasia Syndromes and Secondary AML
Uncategorized
Non-CME Credit Course
Cancer and Thrombosis What is the Role of Direct Oral Anticoagulants?
Uncategorized
Non-CME Credit Course
Chimeric Antigen Receptor (CAR) T Cell Therapy - Progress and Challenges
Uncategorized
Non-CME Credit Course
Advances in the Treatment of Triple-Negative Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
Peripheral T-Cell Lymphoma: Novel Agents & New Horizons
Uncategorized
Non-CME Credit Course
Immunotherapies in Gynecologic Malignancies
Uncategorized
Non-CME Credit Course
Small Cell and Neuroendocrine Carcinoma of The Lung
Uncategorized
Non-CME Credit Course
Colon Cancer - Are We Making Progress
Uncategorized
Non-CME Credit Course
Updates in Pancreatic and Biliary Cancers
Uncategorized
Non-CME Credit Course
Updates on Emesis, Neutropenia and Bone Metastases
Uncategorized
Non-CME Credit Course
ASCO Update on Sarcomas
Uncategorized
Non-CME Credit Course
ALK Mutant NSCLC
Uncategorized
Non-CME Credit Course
Melanoma- Novel Therapies Including Immunotherapy
Uncategorized
Non-CME Credit Course
Immunotherapy in Colorectal Cancer & MSI-High Solid Cancers
Uncategorized
Non-CME Credit Course
Neuroendocrine Tumors of the Lung - A Spectrum of Clinical Challenges
Uncategorized
Non-CME Credit Course
Brain Tumors
Uncategorized
Non-CME Credit Course
Anti-HER2 Therapies in Breast Cancer: Adjuvant and Neodjuvant
Uncategorized
Non-CME Credit Course
ER/PR and CDK Pathways in the Management of ER+ Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
CAR-T Cells: Learning How to Deal with Complications
Uncategorized
Non-CME Credit Course
Health, Wellness and Cancer Prevention
Uncategorized
Non-CME Credit Course
Other Driver Mutations: ROS-1, RET, HER-2, MET & Exon 20 Insertions
Uncategorized
Non-CME Credit Course
EGFR & ALK: Where are We Now
Uncategorized
Non-CME Credit Course
Integrative Survivorship in Cancer Care
Uncategorized
Non-CME Credit Course
Myeloma Treatment: Non-transplant and Transplant Options
Uncategorized
Non-CME Credit Course
Agnostic Tumor Drug Development
Uncategorized
Non-CME Credit Course
CLL and CML
Uncategorized
Non-CME Credit Course
Prostate Cancer Management from Early Biochemical Recurrence to HRPC
Uncategorized
Non-CME Credit Course
Immunotherapy of Kidney and Bladder Cancer
Uncategorized
Non-CME Credit Course
Role of Germline Testing for Breast Cancer Susceptibility Mutations
Uncategorized
Non-CME Credit Course
Immunotherapy and Side Effect Management: Challenging Cases
Uncategorized
Non-CME Credit Course
Non-Hodgkin and Hodgkin Lymphomas
Uncategorized
Non-CME Credit Course
Targeted Therapies in Ovarian & Other Gynecologic Cancers
Uncategorized
Non-CME Credit Course
Supportive Care in Oncology: Anemia, Neutropenia, Emesis, & Bone Metastases
Uncategorized
Non-CME Credit Course
Acute Myeloid and Lymphoid Leukemias
Uncategorized
Non-CME Credit Course
Pancreatic, Biliary Tract and Hepatocellular Carcinoma
Uncategorized
Non-CME Credit Course
Melanoma: Beyond Checkpoint Inhibitors
Uncategorized
Non-CME Credit Course
Immunotherapy in Head and Neck Cancer
Uncategorized
Non-CME Credit Course
Panel_ Translating Clinical Trials' Results into Clinical Practice
Uncategorized
Non-CME Credit Course
Panel-Optimal Therapies in Genitourinary Cancers
Uncategorized
Non-CME Credit Course
Panel-Challenging Cases in Breast Cancer
Uncategorized
Non-CME Credit Course
Advances in Oncology: Breast Cancer Update 2018
Uncategorized
Non-CME Credit Course
Optimizing Immunotherapy with Radiation
Uncategorized
Non-CME Credit Course
New Developments in Lung Cancer Therapeutics
Uncategorized
Non-CME Credit Course
Advances in Gastrointestinal Malignancies
Uncategorized
Non-CME Credit Course
State of the Art: CART-T Cell Therapy in Lymphoma
Uncategorized
Non-CME Credit Course
Hormone Sensitive Metastatic Prostate Cancer
Uncategorized
Non-CME Credit Course
Renal Cell Carcinoma Navigating a Maze of Choices
Uncategorized
Non-CME Credit Course
Small Cell Lung Cancer Novel Approaches
Uncategorized
Non-CME Credit Course
GU Cancer and State of the Art: Castration Resistant Prostate Cancer
Uncategorized
Non-CME Credit Course
Urothelial Cancers- New Strategies
Uncategorized
Non-CME Credit Course
Biomarkers in NSCLC Current Status and Future Directions
Uncategorized
Non-CME Credit Course
Ovarian Cancer Update: PARP Inhibitors in Ovarian Cancer
Uncategorized
Non-CME Credit Course
Cutaneous Melanoma, New Developments for 2018 and Beyond
Uncategorized
Non-CME Credit Course
Immunotherapy for Advanced NSCLC
Uncategorized
Non-CME Credit Course
What's New in Hematopoietic Stem Cell Transplantation?
Uncategorized
Non-CME Credit Course
Targeted Therapy for NSCLC
Uncategorized
Non-CME Credit Course
Lung Cancer Case
Uncategorized
Non-CME Credit Course
Colon Cancer State of the Art
Uncategorized
Non-CME Credit Course
New Developments in Pancreatic Cancer
Uncategorized
Non-CME Credit Course
Predictive Biomarkers for Immunotherapy: Non-Small Cell Lung Cancer as a Model of Tumor Heterogeneity
Uncategorized
Non-CME Credit Course
A Complicated Case of Gastric Cancer
Uncategorized
Non-CME Credit Course
Challenging Case #2: Genitourinary Cancer
Uncategorized
Non-CME Credit Course
Systemic Immunotherapy Combinations
Uncategorized
Non-CME Credit Course
Hepatocellular Cancer Latest Advances
Uncategorized
Non-CME Credit Course
Updates in Multiple Myeloma
Uncategorized
Non-CME Credit Course
Emerging Systematic Treatments for Head and Neck Cancers
Uncategorized
Non-CME Credit Course
Gynecologic Cancer
Uncategorized
Non-CME Credit Course
EGFR: Common and Uncommon Mutations and What Is Next for This Patient Population
Uncategorized
Non-CME Credit Course
ALK-Altered Non-Squamous NSCLC Options and Sequence
Uncategorized
Non-CME Credit Course
Updates in the Management of HER-2 Positive Breast Cancer
Uncategorized
Non-CME Credit Course
How to Handle the Onco-Geriatric Patient: Facts and Myth
Uncategorized
Non-CME Credit Course
Incorporating Immunotherapy and Novel Biological Agents in Breast Cancer: New Horizons
Uncategorized
Non-CME Credit Course
Surfing Between Therapeutic Options for HRPC
Uncategorized
Non-CME Credit Course
Update on the Treatment of Small Cell Lung Cancer and Neuroendocrine Lung Cancers
Uncategorized
Non-CME Credit Course
Squamous Cell Carcinoma Standard and Novel Targets.
Uncategorized
Non-CME Credit Course
The New Face Of Oral Cancer
Uncategorized
Non-CME Credit Course
Angiogenesis, mTor pathway, and other Therapeutics for Kidney Cancer
Uncategorized
Non-CME Credit Course
Management of Thyroid and Thymic Carcinomas
Uncategorized
Non-CME Credit Course
What Lies Beyond EGFR, ALK And ROS1 Targeted Therapies?
Uncategorized
Non-CME Credit Course
What to do About ONJ in the Osteoporosis Patient?
Uncategorized
Non-CME Credit Course
Updates in Esophageal and Gastric Cancers
Uncategorized
Non-CME Credit Course
Breast Cancer Cases
Uncategorized
Non-CME Credit Course
Inhibiting CDK4/6, PIK3CA, and PARP in mBC
Uncategorized
Non-CME Credit Course
Endocrine Therapy in the Neoadjuvant and Adjuvant Setting: ER+ HER-2 Normal Node Negative and Node Positive Breast Cancer
Uncategorized
Non-CME Credit Course
The Management of HER2+ Breast Cancer: A Rapidly Changing Frontier
Uncategorized
Non-CME Credit Course
Updates in Stem Cell Transplantation and CAR-T Therapy for Heme Malignancies
Uncategorized
Non-CME Credit Course
Chronic Lymphocytic Leukemia: Practice Updates in Treatment-Naive and Relapse Disease
Uncategorized
Non-CME Credit Course
Treatment Conundrums in Myeloma: Whats New in 2022?
Uncategorized
Non-CME Credit Course
Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications
Uncategorized
Non-CME Credit Course
How to Choose Front- Line Therapy for Metastatic NSCLC Without Driver Mutations
Uncategorized
Non-CME Credit Course
Neo-Adjuvant and Adjuvant Immunotherapy for Non-Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
Uncommon Mutations/ Fusions: EGFRex20, RET, MET, HER2, NRG1
Uncategorized
Non-CME Credit Course
Dealing with EGFRex19del & L858R, ALK, and K-RasG12C Genetic Aberrations
Uncategorized
Non-CME Credit Course
Soft Tissue Sarcoma
Uncategorized
Non-CME Credit Course
Targeted Therapy for HNSCC and Thyroid Cancer
Uncategorized
Non-CME Credit Course
Novel Innovations in Proton Therapy
Uncategorized
Non-CME Credit Course
Toxicity Management of Novel Agents in Lung Cancer
Uncategorized
Non-CME Credit Course
Updates in Renal Cell Carcinoma
Uncategorized
Non-CME Credit Course
Roundtable Discussion
Uncategorized
Non-CME Credit Course
Updates in Targeted Therapy and Percision Oncology
Uncategorized
Non-CME Credit Course
Updates on FL and CLL from the ASH 2021 Meeting
Uncategorized
Non-CME Credit Course
Triple Negative Breast Cancer: Optimal Neoadjuvant Therapy and New Directions
Uncategorized
Non-CME Credit Course
Squamous NSCLC and Small Cell Lung Cancer Update
Uncategorized
Non-CME Credit Course
New Approaches in the Managment of HER2+ Breast Cancers
Uncategorized
Non-CME Credit Course
New Therapies for Squamous Cell and Small Cell Lung Carcinomas
Uncategorized
Non-CME Credit Course
Non-Small Cell Lung Cancer: EGFR, ALK, & K-Ras Pathways
Uncategorized
Non-CME Credit Course
Targeted Therapy in Sarcomas and Gastrointestinal Stromal Tumors
Uncategorized
Non-CME Credit Course
Targeted Therapy & Immunotherapy in HNSCC
Uncategorized
Non-CME Credit Course
Overview of Gastric & Esophageal Cancers
Uncategorized
Non-CME Credit Course
Pancreatic and Biliary Cancers: Moving the Bar Up?
Uncategorized
Non-CME Credit Course
Indentification and Management of Tyrosine Kinase Inhibitors (TKIs) Toxicities
Uncategorized
Non-CME Credit Course
What is New On the Treatment of Gynecologic Cancers
Uncategorized
Non-CME Credit Course
Neo-Adjuvant and Adjuvant Immuntherapy for Non-Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
How Do I Treat Stage IV TNBC
Uncategorized
Non-CME Credit Course
What's New in HER2- Targeted Therapy for Breast Cancer?
Uncategorized
Non-CME Credit Course
Allogenic Stem Cell Treatment in Post ET Myelofibrosis
Uncategorized
Non-CME Credit Course
Atypical Chronic Lymphocytic Leukemia
Uncategorized
Non-CME Credit Course
Non-Hodgkin's Lymphoma
Uncategorized
Non-CME Credit Course
Plasma Cell Disorder
Uncategorized
Non-CME Credit Course
Survivorship and Pallative Medicine in Cancer Care
Uncategorized
Non-CME Credit Course
Current Status and Future Potential of Proton Therapy
Uncategorized
Non-CME Credit Course
The Lois O’Grady Lectureship: Personalizing Pancreatic Cancer Medicine
Uncategorized
Non-CME Credit Course
State of the Art in Gastrointestinal Cancers
Uncategorized
Non-CME Credit Course
Leveraging Radiogenomics in Cancer Care
Uncategorized
Non-CME Credit Course
The Future of Targeted Therapy in Lung Cancer
Uncategorized
Non-CME Credit Course
Parp Inhibitors and Chemotherapy for Breast Cancer
Uncategorized
Non-CME Credit Course
Hormonal Therapy in Breast Cancer
Uncategorized
Non-CME Credit Course
Diffuse Large B-Cell Lymphoma: Updates and Future Directions
Uncategorized
Non-CME Credit Course
Chronic Lymphocytic and Myeloid Leukemias
Uncategorized
Non-CME Credit Course
Predictive and Prognostic: Value of TMB, MSI and PD-L1 in Liquid and Solid Tumor Specimens.
Uncategorized
Non-CME Credit Course
Liquid Biopsies in Lung Cancer
Uncategorized
Non-CME Credit Course
Prostate and Bladder Cancer
Uncategorized
Non-CME Credit Course
Gynecologic Malignancies
Uncategorized
Non-CME Credit Course
How to Choose Front Line Therapy for Metastatic NSCLC
Uncategorized
Non-CME Credit Course
Uncommon Mutations: RET, MET, NTRK, & BRAF
Uncategorized
Non-CME Credit Course
EGFR/ALK and ROS-1 Lung Cancer Management
Uncategorized
Non-CME Credit Course
Systemic and Combined Therapy for Brain Malignancies and Soft Tissue Sarcomas
Uncategorized
Non-CME Credit Course
Cancer Survivorship: What are the Currents Standards of Care in Solid Tumors
Uncategorized
Non-CME Credit Course
Biosimilars, Beyond the Scientific Review
Uncategorized
Non-CME Credit Course
Integrative Medicine in Cancer Care What the Patients Should Know?
Uncategorized
Non-CME Credit Course
Management of Immunotherapy Related Adverse Events in Solid Tumors
Uncategorized
Non-CME Credit Course
Front Line Metastatic NSCLC
Uncategorized
Non-CME Credit Course
Checkpoint Inhibition in GI Tumors with MSI-H & MMR
Uncategorized
Non-CME Credit Course
Bladder and Kidney Cancers
Uncategorized
Non-CME Credit Course
Melanoma: Metastatic and Adjuvant Therapy
Uncategorized
Non-CME Credit Course
Overview of Gastric and Colon Cancers
Uncategorized
Non-CME Credit Course
Prostate Cancer (no IO): Hormonal, PARP Inhibitors and Other.
Uncategorized
Non-CME Credit Course
Targeted Therapy for Ginecology Oncology Malignancies
Uncategorized
Non-CME Credit Course
SCLC & Squamous NSCLC - New Standards
Uncategorized
Non-CME Credit Course
NTRK, Exon 20 insertions, and Potential Novel Pathways in NSCLC
Uncategorized
Non-CME Credit Course
RET, MET, and BRAF Mutant Lung Cancer Tumors
Uncategorized
Non-CME Credit Course
EGFR & ALK Inhibitors for Mutated Lung Cancer Tumors
Uncategorized
Non-CME Credit Course
Controversial Management in Breast Cancer
Uncategorized
Non-CME Credit Course
Use of CDK4/6 and PIK3CA Inhibitors in Breast Cancer
Uncategorized
Non-CME Credit Course
HER-2 Disease: Neoadjuvant and Adjuvant Therapy
Uncategorized
Non-CME Credit Course
ER/PR+ Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
Challenges in End of Life Care
Uncategorized
Non-CME Credit Course
Supportive Care in Oncology: What’s New in Treating Anemia, Neutropenia, Emesis and Bone Metastases
Uncategorized
Non-CME Credit Course
Management of Common Toxicities Encountered With Checkpoint Inhibitors
Uncategorized
Non-CME Credit Course
B-cell NHL: Highlights from AACR/ASCO
Uncategorized
Non-CME Credit Course
Squamous Cell Carcinoma
Uncategorized
Non-CME Credit Course
Follicular Lymphoma: When to Start Therapy and How To Decide The Optimal Treatment?
Uncategorized
Non-CME Credit Course
Bone Marrow Transplantation: Survivorship Concerns
Uncategorized
Non-CME Credit Course
Treatment-Naïve and First Relapse CLL: What Is The Rationale For Treatment Choice?
Uncategorized
Non-CME Credit Course
How to Choose the Best Therapy for Relapsed Multiple Myeloma Patient
Uncategorized
Non-CME Credit Course
How to Manage Myelodysplasia: Biomarkers and Novel Treatments
Uncategorized
Non-CME Credit Course
Chimeric Antigen Receptor T-cell therapy in 2020: Current Indications
Uncategorized
Non-CME Credit Course
RET, MET, NTRK
Uncategorized
Non-CME Credit Course
EGFR: Common and Uncommon Mutations - What Is Next for These Patient Populations?
Uncategorized
Non-CME Credit Course
ALK Mutant NSCLC: What’s New and Do We Have a Sequencing?
Uncategorized
Non-CME Credit Course
Breast Cancer Case: Part 2
Uncategorized
Non-CME Credit Course
Breast Cancer Case: Part 1
Uncategorized
Non-CME Credit Course
Emerging Biomarkers for Immunotherapy in NSCLC
Uncategorized
Non-CME Credit Course
Common Misunderstandings in IO
Uncategorized
Non-CME Credit Course
Radiotherapy & Immunotherapy Applications in Oncology
Uncategorized
Non-CME Credit Course
Hepatocellular and Biliary Cancers
Uncategorized
Non-CME Credit Course
Advances in the Treatment of Soft Tissue and Bone Sarcomas
Uncategorized
Non-CME Credit Course
Targeted Therapies in Cancer: Is Targeting the Same Mutation Relevant Across Histology and Tumor Type?
Uncategorized
Non-CME Credit Course
Head and Neck Cancer: State of the Art
Uncategorized
Non-CME Credit Course
B-Cell Lymphomas: New Therapeutic Approaches
Uncategorized
Non-CME Credit Course
Renal Cell Cancer: Navigating a Maze of Choices
Uncategorized
Non-CME Credit Course
Advances in Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
Car-T Cells and other Cellular Based Therapies
Uncategorized
Non-CME Credit Course
Immunotherapy in Cancer: A Primer on Biomarkers and Mechanism of Action
Uncategorized
Non-CME Credit Course
How I Treat Stage IV Lung Adenocarcinoma without a Driver Mutation and Negative PD-L1 expression
Uncategorized
Non-CME Credit Course
Keynote Lecture: FDA Perspective on Oncology Drug Development
Uncategorized
Non-CME Credit Course
Predictive Biomarkers for Immunotherapy - Non-Small Cell Lung Cancer (NSCLC) as a Model of Tumor Heterogeneity
Uncategorized
Non-CME Credit Course
Supportive Care in Oncology - Anemia,Neutropenia, Emesis and Bone Metastases
Uncategorized
Non-CME Credit Course
Updates in Immunotherapy & Targeted Therapy in Gastrointestinal Cancers Part 2
Uncategorized
Non-CME Credit Course
Updates in Immunotherapy & Targeted Therapy in Gastrointestinal Cancers Part 1
Uncategorized
Non-CME Credit Course
The New Osteonecrosis Of The Jaws
Uncategorized
Non-CME Credit Course
Case Presentation - Lung - Immunotherapy Toxicity Case, How to Manage and Whether toPermanently Stop or Not
Uncategorized
Non-CME Credit Course
Managing Toxicities from TKI EGFR and ALK Inhibitors
Uncategorized
Non-CME Credit Course
Managing Toxicities from B-RAF and MEKInhibitors
Uncategorized
Non-CME Credit Course
B-Cell Lymphomas including Hodgkin’s Disease
Uncategorized
Non-CME Credit Course
CDK4-6 and PIK3CA Inhibitors in Breast Cancer Management
Uncategorized
Non-CME Credit Course
The Role of Immunotherapy in Breast Cancer
Uncategorized
Non-CME Credit Course
Current Status of Biosimilars and Recent Approvals
Uncategorized
Non-CME Credit Course
Immunologic Therapy for Melanoma
Uncategorized
Non-CME Credit Course
Frontline Therapy in Myeloma - How to Decide the Best Approach
Uncategorized
Non-CME Credit Course
Immunotherapy in Gastrointestinal Tumors (CRC, Esophageal, and other)
Uncategorized
Non-CME Credit Course
Handling the Most Common Toxicities fromIO - Endocrinopathies, Pneumonitis, SkinRash-Pruritus, and Adrenal Insufficiency
Uncategorized
Non-CME Credit Course
Kidney and Bladder Cancers as Targets for Immunotherapy
Uncategorized
Non-CME Credit Course
Managing Expectations-Goals of Care & Family Support
Uncategorized
Non-CME Credit Course
Chronic Lymphocytic Leukemia - Frontline & Relapsed Disease
Uncategorized
Non-CME Credit Course
NTRK, Exon 20 insertions, and Potential Novel Pathways in Lung Cancer
Uncategorized
Non-CME Credit Course
HER-2 Disease - Neo-, Adjuvant,Metastatic Setting
Uncategorized
Non-CME Credit Course
Pancreas and Hepatobiliary Tract
Uncategorized
Non-CME Credit Course
Lung Cancer Immunotherapy
Uncategorized
Non-CME Credit Course
Novel Approaches for Early Stages-Locally Advanced Esophageal and GE Junction Tumors
Uncategorized
Non-CME Credit Course
CAR-T Cells and BMT Learning How to Deal with Complications
Uncategorized
Non-CME Credit Course
Colorectal Cancer - Novel Insights andTherapies (except IO)
Uncategorized
Non-CME Credit Course
Adrienne, Cancer Survivorship Program
Uncategorized
Non-CME Credit Course
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Uncategorized
Non-CME Credit Course
Allogeneic Block Graft vs. Particulate Grafting
Uncategorized
Non-CME Credit Course
Complexity of Delayed Management of Facial Fractures
Uncategorized
Non-CME Credit Course
One Versus Two Plate Management of Subcondylar Mandible Fractures In Oral & Maxillofacial Surgery
Uncategorized
Non-CME Credit Course
RANKL Inhibitors and DIONJ
Uncategorized
Non-CME Credit Course
Breast Cancer Update
Uncategorized
Non-CME Credit Course
State of the Art in Early Hodgkin Lymphoma
Uncategorized
Non-CME Credit Course
New Therapeutic Options in the Myelodysplastic Syndromes
Uncategorized
Non-CME Credit Course
Immunotherapy in Heme Malignancies
Uncategorized
Non-CME Credit Course
Updates in Multiple Myelom
Uncategorized
Non-CME Credit Course
A Cure For (Almost) Every Patient With APL
Uncategorized
Non-CME Credit Course
Phase 1 Trials What’s New in 2019
Uncategorized
Non-CME Credit Course
Nasopharyngeal Carcinoma
Uncategorized
Non-CME Credit Course
Small Cell Lung CancerNovel Approaches 2019
Uncategorized
Non-CME Credit Course
How I Treat Metastatic Urothelial Cancer when IO Therapy Fails
Uncategorized
Non-CME Credit Course
Diffuse Large Cell Lymphoma - The Latest and Greatest
Uncategorized
Non-CME Credit Course
Updates in Targeted Therapies for NSCLC
Uncategorized
Non-CME Credit Course
Management of ImmuneRelated Adverse Events “the guard dog that attacks the owner”
Uncategorized
Non-CME Credit Course
Pancreatic, Biliary Tract & Hepatocellular Carcinoma
Uncategorized
Non-CME Credit Course
Acute Myeloid & Lymphoid Leukemias
Uncategorized
Non-CME Credit Course
Non Hodgkin & Hodgkin Lymphomas
Uncategorized
Non-CME Credit Course
CLL & CML (a lot on the first and not much on the second) Part 1
Uncategorized
Non-CME Credit Course
CLL & CML (a lot on the first and not much on the second) Part 2
Uncategorized
Non-CME Credit Course
Metastatic Colorectal Cancer
Uncategorized
Non-CME Credit Course
Hypermetabolic Syndrome and Cancer
Uncategorized
Non-CME Credit Course
ER-PR & CDK Pathways in the Management of ER+ Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
Anti-HER2 Therapies in Breast Cancer: Adjuvant and Neoadjuvant
Uncategorized
Non-CME Credit Course
The Role of Stereotactic Body Radiation Therapy (SBRT) in Lung Cancer
Uncategorized
Non-CME Credit Course
Therapeutic Strategies Targeting HER2 (ERBB2)
Uncategorized
Non-CME Credit Course
Neoadjuvant Treatment in Thoracic Surgery
Uncategorized
Non-CME Credit Course
Uncommon Oncogenic Drivers in NSCLC
Uncategorized
Non-CME Credit Course
An Introduction to Palliative Care
Uncategorized
Non-CME Credit Course
Targeted and Immune Therapies in Lung Cancer
Uncategorized
Non-CME Credit Course
Optimizing Endocrine Therapy in ER positive, Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
Current Issues in Checkpoint Immunotherapy for NSCLC
Uncategorized
Non-CME Credit Course
Adjuvant Radiotherapy for Breast Cancer
Uncategorized
Non-CME Credit Course
Estrogen Receptor Positive Breast Cancer The Interplay Between Biology and the Logic of Treatment
Uncategorized
Non-CME Credit Course
Therapeutic Strategies Targeting ERBB2 pt 1
Uncategorized
Non-CME Credit Course
Therapeutic Strategies Targeting ERBB2 pt 2
Uncategorized
Non-CME Credit Course
Evolving Treatment Options in EGFR-mutant NSCLC
Uncategorized
Non-CME Credit Course
Oncogene-Driven NSCLC
Uncategorized
Non-CME Credit Course
Immune-Related Adverse Events (irAE) Checkpoint Inhibitors
Uncategorized
Non-CME Credit Course
Melanoma - Novel Therapies IncludingImmunotherapy
Uncategorized
Non-CME Credit Course
Soft Tissues Sarcoma - Updates from ASCO 2019
Uncategorized
Non-CME Credit Course
Combining Radiotherapy with Checkpoint Inhibitors
Uncategorized
Non-CME Credit Course
Brain Tumors - Targeted Therapies,Vaccine and Modality Therapies
Uncategorized
Non-CME Credit Course
Management of Emesis, Neutropenia andBone Metastases - An Oncologic Nursing Perspective
Uncategorized
Non-CME Credit Course
Pancreatic and Biliary Cancers
Uncategorized
Non-CME Credit Course
Small Cell and NeuroendocrineCarcinoma of the Lung
Uncategorized
Non-CME Credit Course
T-Cell NHL - Novel Agents & New Horizons
Uncategorized
Non-CME Credit Course
SRS - Cyberknife and SBRT in Oncology
Uncategorized
Non-CME Credit Course
DOACs in Cancer
Uncategorized
Non-CME Credit Course
Myelodysplasia and Secondary AML
Uncategorized
Non-CME Credit Course
Common and Uncommon Mutations - What Is Next for These Patient Populations
Uncategorized
Non-CME Credit Course
From Bench to Bedside & Back - Breast Cancer Management – Early Clinical Trials
Uncategorized
Non-CME Credit Course
Physician Leadership and the Urgency of the Moment in Medicine
Uncategorized
Non-CME Credit Course
Cancer Care Disparities
Uncategorized
Non-CME Credit Course
Medical Marijuana in Oncology - Myths and Reality
Uncategorized
Non-CME Credit Course
The Entire Sepctrum of Her-2Management in Breast Cancer Disease - All Clinical Settings
Uncategorized
Non-CME Credit Course
CLL - At Recurrence, What is the BestTherapy and What is Comingfrom the Bench Lab
Uncategorized
Non-CME Credit Course
RET, MET, & NTRK in Non-Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
ER-PR Breast Disease - Early Stage, LocallyAdvanced and Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
Handling the Most Common Toxicitiesfrom IO - Endocrinopathies,Pneumonitis, Skin Rash Pruritus and Adrenal Insufficiency
Uncategorized
Non-CME Credit Course
Immunotherapy in Melanoma Skin Cancers
Uncategorized
Non-CME Credit Course
How to Decide which Frontline Therapy in MM After First Relapse Post-Transplant
Uncategorized
Non-CME Credit Course
Oncologic Emergencies The Oncology Nurse Role
Uncategorized
Non-CME Credit Course
Novel Applications of SRS in Oncology-Clinical Cases
Uncategorized
Non-CME Credit Course
Colorectal Cancer - What’s New
Uncategorized
Non-CME Credit Course
Advances In The Treatment of Gynecologic Malignancies
Uncategorized
Non-CME Credit Course
Management of Most Common Toxicities Seen with Checkpoint Inhibitors
Uncategorized
Non-CME Credit Course
Surgical Approaches of Metastatic Colorectal Cancers
Uncategorized
Non-CME Credit Course
Ovarian cancer: Contemporary Management & Clinical Trial Endpoint Considerations
Uncategorized
Non-CME Credit Course
Neoadjuvant and Adjuvant Therapies for Esophageal and Gastric Cancers
Uncategorized
Non-CME Credit Course
HER-2 Disease - Neo-, Adjuvant, Metastatic settings
Uncategorized
Non-CME Credit Course
Modern Antiemetics during Cancer Therapy
Uncategorized
Non-CME Credit Course
Triple Negative Breast Cancer - Still Jurasic Park
Uncategorized
Non-CME Credit Course
Liquid Biopsy in Oncology
Uncategorized
Non-CME Credit Course
New Landscape of Mutant EGFR & ALK Lung Cancer Patients
Uncategorized
Non-CME Credit Course
CAR-T Cell in Oncology
Uncategorized
Non-CME Credit Course
Other Driver Mutations in Lung Cancer - RET,ERBB2, MET, NTRK
Uncategorized
Non-CME Credit Course
How to Monitor and Management Complications from Direct Thrombin Inhibitors
Uncategorized
Non-CME Credit Course
Hormonal Management of Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
Advances in the Management of GBMand other Brain Tumors
Uncategorized
Non-CME Credit Course
Immunotherapy in Neoadjuvant - Adjuvant &Stage III NSCLC
Uncategorized
Non-CME Credit Course
Immunotherapy in Colorectal Cancerand Solid Tumors with Microsatellite Instability-High (MSI-H)
Uncategorized
Non-CME Credit Course
Review Of Coronectomy
Uncategorized
Non-CME Credit Course
Management of Post-Operative Nausea and Vomiting
Uncategorized
Non-CME Credit Course
Microneural Repair of the Inferior Alveolar and Lingual Nerves
Uncategorized
Non-CME Credit Course
Gonzalez, Daya, Prosthodontic Full Mouth Reconstruction of a Trauma Patient-Case Presentation
Uncategorized
Non-CME Credit Course
The Opioid Epidemic – What the Oral and Maxillofacial Surgeon Needs to Know
Uncategorized
Non-CME Credit Course
Fellow Tumor & Reconstructive Surgery
Uncategorized
Non-CME Credit Course
Immediate Loading Implants in Esthetic Zone
Uncategorized
Non-CME Credit Course
The Use of the Intra op CT on the Management of Orbital Reconstruction
Uncategorized
Non-CME Credit Course
Impact of Obesity on Maxillofacial Surgery
Uncategorized
Non-CME Credit Course
New Advances in Breast Cancer
Uncategorized
Non-CME Credit Course
A Vision for Optimizing Patient Outcomes
Uncategorized
Non-CME Credit Course
Challenging Cases in Breast Cancer Moderator
Uncategorized
Non-CME Credit Course
New Therapeutic Options in Acute Myeloid Leukemia
Uncategorized
Non-CME Credit Course
Advances in Radiation Oncology
Uncategorized
Non-CME Credit Course
Optimal Therapeutic Strategies in Multiple Myeloma
Uncategorized
Non-CME Credit Course
Novel Therapeutics for Non-Hodgkins Lymphoma
Uncategorized
Non-CME Credit Course
Emerging Systemic Treatments for Head and Neck Cancers
Uncategorized
Non-CME Credit Course
Update on HER2-positive
Uncategorized
Non-CME Credit Course
Precision Medicine in an Era of Value Based Medicine
Uncategorized
Non-CME Credit Course
Hormone Sensitive Metastatic Prostate Cancer intensification is a winning strategy
Uncategorized
Non-CME Credit Course
Understanding Multi-Cohort Trials
Uncategorized
Non-CME Credit Course
Clinical Trials 101
Uncategorized
Non-CME Credit Course
Immune Checkpoint Inhibitors in Cancer Patients with Autoimmune Disease
Uncategorized
Non-CME Credit Course
Phase 1 Exp Cohorts vs Phase 2 Trials
Uncategorized
Non-CME Credit Course
Neuroendocrine Tumors Emerging Strategies
Uncategorized
Non-CME Credit Course
Patient Derived Xenograft Models
Uncategorized
Non-CME Credit Course
GU Cancer Case
Uncategorized
Non-CME Credit Course
Endocrine Therapy in Breast Cancer State of the Art
Uncategorized
Non-CME Credit Course
Updates in Multiple Myeloma 12 months in 10 minutes
Uncategorized
Non-CME Credit Course
State of the art CAR-T cell therapy in lymphoma
Uncategorized
Non-CME Credit Course
Pharmacokinetics of Anti-Cancer Agents in the CNS
Uncategorized
Non-CME Credit Course
What New in Hematopoietic Stem Cell Transplantation
Uncategorized
Non-CME Credit Course
TNBCBRCA Mutated Tumors
Uncategorized
Non-CME Credit Course
Multiple Myeloma Transplant and Non-transplant Modalities
Uncategorized
Non-CME Credit Course
Immunotherapy for Breast
Uncategorized
Non-CME Credit Course
Combination Immunotherapy for Lung Cancer
Uncategorized
Non-CME Credit Course
Targeted Agents and Chemotherapy in Gynecologic Malignanciess in 2018
Uncategorized
Non-CME Credit Course
Squamous Cell Carcinoma: What are the Standards and Potential Pathways in Development
Uncategorized
Non-CME Credit Course
Treatment of Early-Stage HER2+ Breast Cancer
Uncategorized
Non-CME Credit Course
Prostate Cancer Management
Uncategorized
Non-CME Credit Course
Immunotherapy in Head and Neck Cancer and MSI in Solid Tumors
Uncategorized
Non-CME Credit Course
CLL & CML
Uncategorized
Non-CME Credit Course
Colorectal Cancer: Novel Insights
Uncategorized
Non-CME Credit Course
Immunotherapy for the Treatment of Kidney and Bladder Cancer
Uncategorized
Non-CME Credit Course
Novel Therapies in Metastatic Kidney Cancer
Uncategorized
Non-CME Credit Course
Melanoma: What Else Beyond Checkpoint Inhibitor Pathway?
Uncategorized
Non-CME Credit Course
Supportive Care Reality vs. Perception
Uncategorized
Non-CME Credit Course
Cancer Treatment Induced Bone Loss (CTIBL)_ RANK Ligand, Bisphosphonate, Anti-angiogenesis, and More
Uncategorized
Non-CME Credit Course
Integrative Oncology: Evidence-Based Supportive Care for Patients during Treatment and Survivorship
Uncategorized
Non-CME Credit Course
Familial Hereditary Symdromes in High-risk Breast Cancer Patients_ Genetic Counseling
Uncategorized
Non-CME Credit Course
Marijuana Use in Cancer: Myths and Reality
Uncategorized
Non-CME Credit Course
Other Driver Mutations: cMET, B-RAF, RET, NTRK
Uncategorized
Non-CME Credit Course
Pancreatic, Biliary, and HCC Update
Uncategorized
Non-CME Credit Course
Targeted Therapy for B- and T-cell Non-Hodgkin's Lymphomas
Uncategorized
Non-CME Credit Course
Novel Therapies for BCC and SCC of Skin and Merkel Cell Carcinoma
Uncategorized
Non-CME Credit Course
Chemotherapy and Hormonal Therapy in the Metastatic Setting, ER+ HER2-2- and TNBC
Uncategorized
Non-CME Credit Course
Immunotherapy in Colorectal Cancer
Uncategorized
Non-CME Credit Course
Case Study Immunotherapy
Uncategorized
Non-CME Credit Course
Case Study
Uncategorized
Non-CME Credit Course
Case Study Molecular Testing
Uncategorized
Non-CME Credit Course
Management of EGFR-mutant NSCLC
Uncategorized
Non-CME Credit Course
Case Study on Immunotherapy Reaction
Uncategorized
Non-CME Credit Course
Immunotherapy Related Adverse Reactions
Uncategorized
Non-CME Credit Course
Immunotherapy of Melanoma
Uncategorized
Non-CME Credit Course
Multiple Myeloma Induction, Consolidation and Maintenance Therapy
Uncategorized
Non-CME Credit Course
Stereotactic Radiation Therapy OligoMetastatic Disease
Uncategorized
Non-CME Credit Course
Angiogenesis, mTORpathway, and Other Therapeutics for Kidney Cancer
Uncategorized
Non-CME Credit Course
Role of Immunotherapy in Gynecologic Cancers
Uncategorized
Non-CME Credit Course
Changing the landscape of treatment in Peripheral T-cell Lymphoma
Uncategorized
Non-CME Credit Course
Right Drug for the Right Colorectal Patient Select the Best Initial Therapy
Uncategorized
Non-CME Credit Course
Exploiting the Immunomodulatory Properties of Radiation Therapy
Uncategorized
Non-CME Credit Course
What Lies Beyond EGFR, ALKAND ROS1 Targeted Therapies
Uncategorized
Non-CME Credit Course
Chemoembolization, Radioembolization, and Focal Ablation in Oncology
Uncategorized
Non-CME Credit Course
Pancreatic Cancer
Uncategorized
Non-CME Credit Course
Cancer And Thrombosis
Uncategorized
Non-CME Credit Course
Survivorship in Oncology Importance and Impact in Patient Care
Uncategorized
Non-CME Credit Course
Myelodysplastic Syndromes Is It Time to Incorporate NGS and What Is New in Terms of Therapy
Uncategorized
Non-CME Credit Course
Legislation & Reimbursement
Uncategorized
Non-CME Credit Course
Incorporating Immunotherapy and Novel Biological Agents in Breast Cancer
Uncategorized
Non-CME Credit Course
Update on Chronic Myeloid Leukemia
Uncategorized
Non-CME Credit Course
How To Handle The Onco-Geriatric Patient
Uncategorized
Non-CME Credit Course
Updates in the Management of HER2 Positive Breast Cancer
Uncategorized
Non-CME Credit Course
EGFR Common and Uncommon Mutations & What Is Next For This Patient Population
Uncategorized
Non-CME Credit Course
Immunotherapy for Upper GI Cancers
Uncategorized
Non-CME Credit Course
B-Cell NHL and Hodgkin’s Disease Biologicals, Checkpoint Inhibitors, CAR-T cells
Uncategorized
Non-CME Credit Course
Gynecologic Cancer Recent Advances in Management
Uncategorized
Non-CME Credit Course
ERPR Breast Disease Early Stage, Locally Advanced and Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
Novel Approaches in the Management of Multiple Myeloma
Uncategorized
Non-CME Credit Course
Systemic Therapies for Brain Tumors
Uncategorized
Non-CME Credit Course
Long Term Effects of Cranial Radiotherapy
Uncategorized
Non-CME Credit Course
State of the Art Sequencing of Treatment in Patients with Castration Resistant Prostate Cancer
Uncategorized
Non-CME Credit Course
Treatment of Melanoma Beyond Checkpoint Inhibition
Uncategorized
Non-CME Credit Course
Neoadjuvant Chemotherapy for Early Breast CA
Uncategorized
Non-CME Credit Course
Novel Systemic Therapies for Gastric and Colorectal Cancers
Uncategorized
Non-CME Credit Course
Surgery for Colorectal Tumors
Uncategorized
Non-CME Credit Course
Liquid Biopsy in the Management of Lung Cancer
Uncategorized
Non-CME Credit Course
Management of Metastatic Breast Cancer
Uncategorized
Non-CME Credit Course
Targeted Therapy for B- and T-cell Non-Hodgkins Lymphomas
Uncategorized
Non-CME Credit Course
Other Targeted Agents in NSCLC
Uncategorized
Non-CME Credit Course
Radiation Theraphy and Genomic Interactions in Breast Cancer Patients
Uncategorized
Non-CME Credit Course
Body Changes & Intimacy After Cancer
Uncategorized
Non-CME Credit Course
Management of Precancerous Lesions and Early Esophageal Carcinoma with Endoscopic Advancements
Uncategorized
Non-CME Credit Course
Genetic Abnormalities and Active Targets in Esophageal Cancer
Uncategorized
Non-CME Credit Course
Current Epidemiology and Incidence of Esophageal Cancer: East vs West; Implications on Clinical Trials
Uncategorized
Non-CME Credit Course
Incorporating Immunotherapy in the Management of Cervical Cancer
Uncategorized
Non-CME Credit Course
Prostate and Bladder Cancers: What Have we Learned Over the Past Year?
Uncategorized
Non-CME Credit Course
RCC in 2025: What’s New for the Practicing Oncologist?
Uncategorized
Non-CME Credit Course
Perioperative Immunotherapy in NSCLC
Uncategorized
Non-CME Credit Course
Antibody Drug Conjugates in Lung Cancer
Uncategorized
Non-CME Credit Course
Targeted Therapy and Resistance, New Agents are Coming
Uncategorized
Non-CME Credit Course
New Developments in Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
Artificial Intelligence in Cancer Therapeutics: Fact or Fiction?
Uncategorized
Non-CME Credit Course
Esophageal Carcinoma – Finally Something Practice Changing
Uncategorized
Non-CME Credit Course
Hepatocellular Carcinoma: Are We Finally Making Progress?
Uncategorized
Non-CME Credit Course
Will Biosimilars Reduce Financial Toxicity of Cancer Therapy
Uncategorized
Non-CME Credit Course
Novel Therapies for Aggressive Non-Hodgkin Lymphomas
Uncategorized
Non-CME Credit Course
Treatment of Patients Progressing after BTKi and BCL2i
Uncategorized
Non-CME Credit Course
Sequencing of Therapies for Multiple Myeloma
Uncategorized
Non-CME Credit Course
Antibody Drug Conjugates for HER2 Negative Breast Cancer: Advancing Breast Cancer Management
Uncategorized
Non-CME Credit Course
Colorectal Cancer Genomic Profiling, Tumor-Informed or Tumor Naïve. Primetime and Utility?
Uncategorized
Non-CME Credit Course
Esophageal and Gastric Carcinomas: Moving the Bar Up after ESMO 2024
Uncategorized
Non-CME Credit Course
HCC and Pancreatic Cancer: Novel Therapies after ASCO and ESMO 2024
Uncategorized
Non-CME Credit Course
What is New After ASCO and ESMO 2024 in Colon and Rectal Cancer Management?
Uncategorized
Non-CME Credit Course
New Endocrine and Targeted Agents for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
Uncategorized
Non-CME Credit Course
Post-Neoadjuvant Therapy after Residual Disease: How to Approach This Problem?
Uncategorized
Non-CME Credit Course
B-cell and T-cell NHL Challenges
Uncategorized
Non-CME Credit Course
Updates in CML and CLL
Uncategorized
Non-CME Credit Course
Targeted Therapy in NSCLC
Uncategorized
Non-CME Credit Course
Immunotherapy in NSCLC: Advanced Disease and Resistance
Uncategorized
Non-CME Credit Course
Prostate Cancer: What is the Best Combination Therapy?
Uncategorized
Non-CME Credit Course
Gynecologic Malignancies: New Therapeutic Developments
Uncategorized
Non-CME Credit Course
Updates in Kidney and Bladder Cancers: Immunotherapy and Targeted Therapy
Uncategorized
Non-CME Credit Course
Latest Advances in Gastrointestinal Cancers
Uncategorized
Non-CME Credit Course
Therapeutic Advances in Gynecologic Oncology
Uncategorized
Non-CME Credit Course
ALL REVOLUTION: Improving Outcomes for ALL
Uncategorized
Non-CME Credit Course
Targeting the Microbiome and Optimizing Immunotherapy in Cancer
Uncategorized
Non-CME Credit Course
Targeting RAS-RAF-MAPK Pathway
Uncategorized
Non-CME Credit Course
Hippo-Yap Pathway
Uncategorized
Non-CME Credit Course
Novel Targets in Hematologic Malignancies
Uncategorized
Non-CME Credit Course
AML and MDS: New Directions
Uncategorized
Non-CME Credit Course
Systemic Therapy in Urothelial Carcinoma
Uncategorized
Non-CME Credit Course
Management of Renal Cell Carcinoma
Uncategorized
Non-CME Credit Course
Castration Resistant Prostate Cancer: What is the Optimal Strategy?
Uncategorized
Non-CME Credit Course
State of the Art - Hormone Sensitive Prostate Cancer
Uncategorized
Non-CME Credit Course
Precision Oncology and Landmark Advances in GU Malignancies
Uncategorized
Non-CME Credit Course
Updates in Locally Advanced Unresectable (Stage III) NSCLC
Uncategorized
Non-CME Credit Course
Advances in Limited and Extensive Stage Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
Updates in NSCLC Targeted Therapy
Uncategorized
Non-CME Credit Course
Updates in Immunotherapy for Metastatic Lung Cancer
Uncategorized
Non-CME Credit Course
New Developments in Esophageal and Gastric Cancer
Uncategorized
Non-CME Credit Course
Recent Advances in Colorectal Cancer
Uncategorized
Non-CME Credit Course
Updates in the Management of Pancreatic Cancer
Uncategorized
Non-CME Credit Course
Advances in Cellular Therapies for Cancer
Uncategorized
Non-CME Credit Course
Advances in Non-PD(L)1 Immunotherapies in Solid Tumors
Uncategorized
Non-CME Credit Course
Perioperative Therapy and Predictive Biomarkers in Early Stage Non Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
Overview on How to Submit a Clinical Letter of Intent (LOI) to NCI/CTEP
Uncategorized
Non-CME Credit Course
Expansion Cohorts in Early Phase Clinical Trials: Valuable or Not?
Uncategorized
Non-CME Credit Course
Everything You Wanted To Know About the Pitt-Cal U54 Pharmacokinetics Resource Laboratory
Uncategorized
Non-CME Credit Course
2024 Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
2024 Metastatic Non-Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
Triple Negative Breast Cancer Updates
Uncategorized
Non-CME Credit Course
HER2-Positive Breast Cancer Updates
Uncategorized
Non-CME Credit Course
Lymphoma and CLL 2024 Updates
Uncategorized
Non-CME Credit Course
Global Oncology: Impact and Updates
Uncategorized
Non-CME Credit Course
Clinical Applications for Liquid Biopsy in GU Cancers Update
Uncategorized
Non-CME Credit Course
Bladder / Urothelial Cancer Updates
Uncategorized
Non-CME Credit Course
Renal Cell Carcinoma Updates
Uncategorized
Non-CME Credit Course
ASCO GI 2024 Updates
Uncategorized
Non-CME Credit Course
Head and Neck Cancer 2024 Updates
Uncategorized
Non-CME Credit Course
BRAF and NTRK Inhibitors in NSCLC
Uncategorized
Non-CME Credit Course
Exon 20 Insertions - What Will be the Ideal Therapy?
Uncategorized
Non-CME Credit Course
STK11, KEAP and TP53 as Co-Mutations with Bad Prognosis - Is there a Predictive Role?
Uncategorized
Non-CME Credit Course
Resistance to KRAS Inhibitors
Uncategorized
Non-CME Credit Course
The Era of Antibody-Drug Conjugates (ADCs) and Bi-Specifics
Uncategorized
Non-CME Credit Course
Role of Radiation Therapy in SCLC
Uncategorized
Non-CME Credit Course
The Future of SCLC Treatment: Potential Agents and Where Are We Going?
Uncategorized
Non-CME Credit Course
Treatment for SCLC in 2024: Where Are We At?
Uncategorized
Non-CME Credit Course
Progress in Biomarkers for SCLC – Are We Ready for Implementation into Routine Clinical Practice?
Uncategorized
Non-CME Credit Course
Moving the Bar Beyond PACIFIC. What is the Best Consolidation Therapy for People with Actionable and Non-Actionable Genes?
Uncategorized
Non-CME Credit Course
Combining Immunotherapy with Radiation for LA-NSCLC
Uncategorized
Non-CME Credit Course
Assessing Resectability in Stage III NSCLC
Uncategorized
Non-CME Credit Course
Update Progress in Targeted Therapies for Early-Stage NSCLC
Uncategorized
Non-CME Credit Course
Which Patients Need Adjuvant Therapy?
Uncategorized
Non-CME Credit Course
Debate- Is Perioperative Immunotherapy the New Standard of Care? No.
Uncategorized
Non-CME Credit Course
Debate- Is Perioperative Immunotherapy the New Standard of Care? Yes.
Uncategorized
Non-CME Credit Course
Perioperative Chemo/Immunotherapy and Surgical Outcomes
Uncategorized
Non-CME Credit Course
What is the Best Way to Assess Response to Therapy? Is Complete Pathologic Response the Best Surrogate?
Uncategorized
Non-CME Credit Course
Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms
Uncategorized
Non-CME Credit Course
Incidental Pulmonary Nodule Programs (IPNs) – What are Best Practices for Monitoring and Diagnosing?
Uncategorized
Non-CME Credit Course
Existing and Emerging Tests for Cancer Interception: How Low do We have to Go (with the LOD)? Does Methylation Help?
Uncategorized
Non-CME Credit Course
Lung Cancer Screening Programs: How do We ‘Take it to the Next Level’ to Improve Lung Cancer Outcomes?
Uncategorized
Non-CME Credit Course
2025 MCM | Myelodysplasia
Uncategorized
Non-CME Credit Course
Progress in Neoadjuvant Therapy for Breast Cancer: Reviewing the Role of Immunotherapy, Endocrine and Anti-Her-2 Therapy
Uncategorized
Non-CME Credit Course
Multiple Myeloma in 2024
Uncategorized
Non-CME Credit Course
New Developments in Thrombosis Management in Cancer
Uncategorized
Non-CME Credit Course
Recent Updates in Multiple Myeloma
Uncategorized
Non-CME Credit Course
Growing UP! Progress in Treatment of Young Adults with ALL
Uncategorized
Non-CME Credit Course
Immunotherapy for Breast Cancer: When to Use and Future Directions
Uncategorized
Non-CME Credit Course
Policy Update - Financial Survival: It’s not Easy Being Green!!
Uncategorized
Non-CME Credit Course
Minimizing Waste by Maximizing BUDs: Immediate Use Compounding for Biologics
Uncategorized
Non-CME Credit Course
Clinical Update: Biosimilars to Adalimumab
Uncategorized
Non-CME Credit Course
The Art and the Science of Formulary Management | Acute to Ambulatory Strategies
Uncategorized
Non-CME Credit Course
Clinical Update: Cell and Gene Therapy, the Future of Medicine
Uncategorized
Non-CME Credit Course
Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies (Part 2)
Uncategorized
Non-CME Credit Course
Targeted Therapy in Sarcomas Beyond GIST
Uncategorized
Non-CME Credit Course
Targeted Therapy for Ovarian and Uterine Tumors
Uncategorized
Non-CME Credit Course
Brain Tumors: Is Time for Personalized Medicine?
Uncategorized
Non-CME Credit Course
Developing Targeted Therapy for Genito-Urinary Malignancies
Uncategorized
Non-CME Credit Course
Cholangiocarcinoma, Hepatoma and Pancreas: What’s New
Uncategorized
Non-CME Credit Course
Novel Advances in Colorectal Cancer Other Than Immunotherapy
Uncategorized
Non-CME Credit Course
Developments in Esophageal and Gastric Tumors
Uncategorized
Non-CME Credit Course
Immunotherapy and Exciting Updates in Advanced Prostate Cancer
Uncategorized
Non-CME Credit Course
Immunotherapy for Gynecology-Oncology Malignancies: Is There Still Time for Progress?
Uncategorized
Non-CME Credit Course
Establishing Immunotherapy Management in Gastrointestinal Cancers
Uncategorized
Non-CME Credit Course
Immunotherapy and Targeted Agents in Head/Neck Cancer
Uncategorized
Non-CME Credit Course
Novel Immunotherapy Approach and Targeted Therapy in Melanoma
Uncategorized
Non-CME Credit Course
Perioperative Immunotherapy in Non-Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
Advances in Surgical Treatments for the Breast Cancer Patient
Uncategorized
Non-CME Credit Course
Changing Delivery of Chemotherapy for Breast Cancer: The Era of Antibody Drug Conjugates
Uncategorized
Non-CME Credit Course
Optimal Treatment for Early Stage HER2 Positive Breast Cancer: Tailoring Treatment to Response
Uncategorized
Non-CME Credit Course
Sequencing Endocrine Therapy and Targeted Agents for the Treatment of Metastatic HR+/HER2- Breast Cancer
Uncategorized
Non-CME Credit Course
Current and Future Directions of Immunotherapy for Breast Cancer
Uncategorized
Non-CME Credit Course
Case Presentation: CLL
Uncategorized
Non-CME Credit Course
Case Presentation: Cellular Therapy CAR-T
Uncategorized
Non-CME Credit Course
Case Presentation: NHL
Uncategorized
Non-CME Credit Course
Case Presentation: Myeloma
Uncategorized
Non-CME Credit Course
Case Presentation: Acute Leukemia
Uncategorized
Non-CME Credit Course
Liquid Biopsies to Guide Targeted Therapy
Uncategorized
Non-CME Credit Course
Addressing Social Determinants of Health (SDOH)
Uncategorized
Non-CME Credit Course
The Challenges of Biosimilars in the Daily Oncology Practice?
Uncategorized
Non-CME Credit Course
Management of Adverse Events of Check Point Inhibitors (CPI) and Antibody Drug Conjugates (ADC) in Solid Tumors
Uncategorized
Non-CME Credit Course
Melanoma- Have we Hit a Plateau or are we Making Progress
Uncategorized
Non-CME Credit Course
Immunotherapy For Triple Negative Breast Cancer Optimal Chemotherapy Partners, New Directors, And Managing Toxicity
Uncategorized
Non-CME Credit Course
Recent Advances in Radiation Treatment for Early-Stage Breast Cancer
Uncategorized
Non-CME Credit Course
Updates in Lymphomas
Uncategorized
Non-CME Credit Course
Updates in the Surgical Management of Head and Neck Cancers
Uncategorized
Non-CME Credit Course
New Advances in the Medical Management of Head and Neck Cancers
Uncategorized
Non-CME Credit Course
What’s After PACIFIC? Can We Raise the Bar?
Uncategorized
Non-CME Credit Course
What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?
Uncategorized
Non-CME Credit Course
Updates in Bispecific Antibodies in NSCLC
Uncategorized
Non-CME Credit Course
TROP-2 and AXL as Targets in NSCLC
Uncategorized
Non-CME Credit Course
The Role of Co-Mutations with Immunotherapy Response in NSCLC
Uncategorized
Non-CME Credit Course
The New Role of Microbiome in Lung Cancer Immunotherapy
Uncategorized
Non-CME Credit Course
The Importance of TIME in Cancer Fight: How to Target It?
Uncategorized
Non-CME Credit Course
Targeting CEACAM5 and ROR1/ROR2 in NSCLC
Uncategorized
Non-CME Credit Course
Systemic Therapies for Mesothelioma
Uncategorized
Non-CME Credit Course
Strategies to Target Minimal Residual Disease
Uncategorized
Non-CME Credit Course
Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach
Uncategorized
Non-CME Credit Course
Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)
Uncategorized
Non-CME Credit Course
ROS-1 & B-Raf Inhibitors: New Developments
Uncategorized
Non-CME Credit Course
Role of SHP2 Inhibitors Alone or in Combination
Uncategorized
Non-CME Credit Course
Role of Radiotherapy in TIME: Good? Bad? Don’t know?
Uncategorized
Non-CME Credit Course
Role of Interleukins in TIME to Improve Immunotherapy Efficacy
Uncategorized
Non-CME Credit Course
RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?
Uncategorized
Non-CME Credit Course
Radiation Induced Immune-Response in NSCLC
Uncategorized
Non-CME Credit Course
Predictive Biomarkers for SCLC
Uncategorized
Non-CME Credit Course
PARP Inhibitors in SCLC
Uncategorized
Non-CME Credit Course
Pan-KRAS Inhibitors: Where are We Going?
Uncategorized
Non-CME Credit Course
Overcoming T-Cell Exhaustion
Uncategorized
Non-CME Credit Course
Optimal Surgical Approach for Mesothelioma
Uncategorized
Non-CME Credit Course
Optimal Management of Limited Stage SCLC
Uncategorized
Non-CME Credit Course
Optimal Management of Extensive SCLC (1st and 2nd Line)
Uncategorized
Non-CME Credit Course
NRG1 as Target in NSCLC?
Uncategorized
Non-CME Credit Course
Novel Therapies for Thymic Malignancies
Uncategorized
Non-CME Credit Course
Neoadjuvant Immunotherapy Position
Uncategorized
Non-CME Credit Course
MRD to Decide Perioperative Management in the Era of Immuno-Oncology
Uncategorized
Non-CME Credit Course
Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?
Uncategorized
Non-CME Credit Course
Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection
Uncategorized
Non-CME Credit Course
Mechanisms of Resistance to ALK Inhibitors
Uncategorized
Non-CME Credit Course
Lack of Equity in Clinical Outcomes in African American and Hispanics with NSCLC
Uncategorized
Non-CME Credit Course
KRAS: Deciphering the Mechanism of Resistance To First Generation KRAS Inhibitors
Uncategorized
Non-CME Credit Course
KRAS mutant NSCLC: What is the Standard of Care Now?
Uncategorized
Non-CME Credit Course
How to Start a Lung Cancer Screening Program
Uncategorized
Non-CME Credit Course
How to Rescue Patients from Osimertinib Resistance
Uncategorized
Non-CME Credit Course
How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps?
Uncategorized
Non-CME Credit Course
HER-3 as a New Target in NSCLC
Uncategorized
Non-CME Credit Course
Health Care Disparities in Lung Cancer Genomic Profiling
Uncategorized
Non-CME Credit Course
Future Challenges for Immunotherapy in the Fight Against NSCLC
Uncategorized
Non-CME Credit Course
Frontline: What are We Adding to Checkpoint Inhibitors and Chemotherapy?
Uncategorized
Non-CME Credit Course
Exon 20 and Uncommon EGFR Sensitive Mutations
Uncategorized
Non-CME Credit Course
Developing New Anti-CTL4s for NSCLC: Is There Any Role?
Uncategorized
Non-CME Credit Course
CAR-T Cell in NSCLC: Is it Feasible?
Uncategorized
Non-CME Credit Course
Building the Case for HER-2 Inhibitors in NSCLC
Uncategorized
Non-CME Credit Course
Brain Radiotherapy in SCLC: When?
Uncategorized
Non-CME Credit Course
Biomarkers for Perioperative Immunotherapy?
Uncategorized
Non-CME Credit Course
Best Surgical Approaches for Stage III NSCLC
Uncategorized
Non-CME Credit Course
Best Approaches for First Line EGFR Mutant NSCLC
Uncategorized
Non-CME Credit Course
ALK in Front Line Therapy: Second or Third Generation TKI Inhibitors. What Can Help Us to Choose the Best Therapeutic Agent?
Uncategorized
Non-CME Credit Course
Adjuvant Immunotherapy Position
Uncategorized
Non-CME Credit Course
Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies
Uncategorized
Non-CME Credit Course
Metastatic NSCLC Immunotherapy Updates
Uncategorized
Non-CME Credit Course
Metastatic Targeted Therapy Updates
Uncategorized
Non-CME Credit Course
Advances in Value Based Care
Uncategorized
Non-CME Credit Course
How I Treat Triple Negative Breast Cancer in 2023
Uncategorized
Non-CME Credit Course
2023 Gyn Oncology Updates
Uncategorized
Non-CME Credit Course
How I Treat Metastatic HER2+/HER2-Low Breast Cancer in 2023
Uncategorized
Non-CME Credit Course
How I Treat Metastatic Renal Cell Cancer in 2023
Uncategorized
Non-CME Credit Course
How I Treat Metastatic Prostate Cancer in 2023
Uncategorized
Non-CME Credit Course
How I Treat Metastatic Bladder Cancer in 2023
Uncategorized
Non-CME Credit Course
How I Treat Metastatic Esophageal and Gastric Cancer in 2023
Uncategorized
Non-CME Credit Course
How I Treat Metastatic Colorectal Cancer in 2023
Uncategorized
Non-CME Credit Course
How I Treat AML in 2023
Uncategorized
Non-CME Credit Course
How I Treat Multiple Myeloma in 2023
Uncategorized
Non-CME Credit Course
Novel Treatment for Unresectable Stage III NSCLC
Uncategorized
Non-CME Credit Course
Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates
Uncategorized
Non-CME Credit Course
Management of Neurological Toxicities from Immunotherapy: Diagnosis, Assessement and Therapy
Uncategorized
Non-CME Credit Course
Management of Osteonecrosis of Jaw and Other Complications from Bisphosphonate and/or RANK Ligand Inhibitors
Uncategorized
Non-CME Credit Course
Walking Alongside Patients in Cancer
Uncategorized
Non-CME Credit Course
Thymoma and Thymic Carcinomas
Uncategorized
Non-CME Credit Course
Thrombophilia & Thrombosis in Cancer Patients: Novel Advances
Uncategorized
Non-CME Credit Course
The Art-of-Medicine in Treating Chronic Lymphocytic Leukemia
Uncategorized
Non-CME Credit Course
Survivorship in the Modern Era of Cancer Care: Goals, Measures, and Outcomes
Uncategorized
Non-CME Credit Course
Small Cell Lung Cancer: 1L and Beyond
Uncategorized
Non-CME Credit Course
Redefining Treatment Algorithms in B-cell Lymphomas: A Focus on CAR-T Cell TherapyLymphoma
Uncategorized
Non-CME Credit Course
Pre-Operative and Metastatic Setting Biomarkers for Immunotherapy in Lung Cancer
Uncategorized
Non-CME Credit Course
Pancreas, Hepatic and Cholangiocarcinoma: Advances in 2023
Uncategorized
Non-CME Credit Course
Novel Therapeutic Advances for DLBCL & Hodgkin’s Disease
Uncategorized
Non-CME Credit Course
Novel RT Approaches in Prostate Cancer
Uncategorized
Non-CME Credit Course
Novel Advances in RT for Oligometastatic Disease
Uncategorized
Non-CME Credit Course
Novel Advances in Mesothelioma
Uncategorized
Non-CME Credit Course
Novel Advances in Head and Neck Cancer: What is after IO?
Uncategorized
Non-CME Credit Course
Neoadjuvant and Adjuvant Immunotherapy in Early Stage Lung Cancer
Uncategorized
Non-CME Credit Course
Navigating Payor Barriers to Access of Oncology Pharmaceuticals: Real-World Case Approach
Uncategorized
Non-CME Credit Course
Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions
Uncategorized
Non-CME Credit Course
Melanoma: What is after immunotherapy? More immunomodulation?
Uncategorized
Non-CME Credit Course
Medical Marijuana: Who, When & How?
Uncategorized
Non-CME Credit Course
Lack of Access to Novel Cancer Therapies: How to Deal and Approach this Problem? Diversity, Equity, & Inclusion
Uncategorized
Non-CME Credit Course
K-RAS and ERBB2 Mutation in NSCLC
Uncategorized
Non-CME Credit Course
Immunotherapy for Breast Cancer: Current and Future Directions
Uncategorized
Non-CME Credit Course
Identifying and Targeting Mechanisms of Resistance to 3rd Generation EGFR Inhibitors
Uncategorized
Non-CME Credit Course
How to Navigate Through Relapsed-Refractory Myeloma Patient
Uncategorized
Non-CME Credit Course
How to Combine RT and Immunotherapy Without Compromising Anti-tumor Effect?
Uncategorized
Non-CME Credit Course
How to Choose the Best 1L in a Newly Diagnosed Multiple Myeloma Patient?
Uncategorized
Non-CME Credit Course
GIST and Soft Tissue Sarcomas: Focus on Personalized Medicine
Uncategorized
Non-CME Credit Course
Geriatric Oncology: Pitfalls to Deliver Good Care in the Elderly Cancer Patient
Uncategorized
Non-CME Credit Course
Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine
Uncategorized
Non-CME Credit Course
Esophageal, Gastric and GE Junction Tumors: What’s New in 2023?
Uncategorized
Non-CME Credit Course
EGFRex20ins, METex14 and RET in NSCLC
Uncategorized
Non-CME Credit Course
Drug Development and New Targeted Agents for Breast Cancer: What Does the Future Hold?
Uncategorized
Non-CME Credit Course
ctDNA in Adjuvant and Metastatic Therapy for GI Cancers: Prime Time?
Uncategorized
Non-CME Credit Course
Bringing Personalized Medicine to Colorectal Cancers
Uncategorized
Non-CME Credit Course
Artificial Intelligence in Oncology Care
Uncategorized
Non-CME Credit Course
ALK: Choosing 1L & Mechanism of Resistance
Uncategorized
Non-CME Credit Course
ADC in NSCLC: TROP2 and HER3 in NSCLC
Uncategorized
Non-CME Credit Course
ADC in NSCLC: CEACAM5 and Teliso-V
Uncategorized
Non-CME Credit Course
Metastatic Lung Immunotherapy Updates
Uncategorized
Non-CME Credit Course
Local Advanced NSCLC Neoadjuvant/ Adjuvant Update
Uncategorized
Non-CME Credit Course
How I treat HER2+ Breast Cancer in 2023
Uncategorized
Non-CME Credit Course
How I Use Liquid Biopsy for GI Cancers in 2023
Uncategorized
Non-CME Credit Course
How I Treat Metastatic Colon Cancer in 2023
Uncategorized
Non-CME Credit Course
Evolution of Renal Cell Cancer Treatments since 2010
Uncategorized
Non-CME Credit Course
How I Treat Prostate Cancer in 2023
Uncategorized
Non-CME Credit Course
Multiple Myeloma Updates 2023
Uncategorized
Non-CME Credit Course
Early Stage TNBC: Reviewing Different Strategies and Management
Uncategorized
Non-CME Credit Course
ADC in Breast Cancer Management
Uncategorized
Non-CME Credit Course
Multiple Myeloma: Triplet? Quadruplet? What is The Best Frontline Therapy and Next Line after First Relapse?
Uncategorized
Non-CME Credit Course
CAR-T Cell as Strategy for the Management of Hematologic Malignancies
Uncategorized
Non-CME Credit Course
Follicular, Marginal Zone and Mantle Cell NHL: Novel Advances
Uncategorized
Non-CME Credit Course
DLBCL & Hodgkin’s Disease
Uncategorized
Non-CME Credit Course
New Developments in Sarcoma Therapy
Uncategorized
Non-CME Credit Course
Ovarian-Uterine & Fallopian Tube Carcinomas
Uncategorized
Non-CME Credit Course
Novel Advances in the Therapy of Kidney and Bladder Carcinomas
Uncategorized
Non-CME Credit Course
Novel Advances in Radiation Oncology Beyond SRS and Proton Therapy: What Is Next?
Uncategorized
Non-CME Credit Course
Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections
Uncategorized
Non-CME Credit Course
Novel Platforms to Assess the Cancer Continuom Using Liquid Biopsy
Uncategorized
Non-CME Credit Course
Oncology Payments Models: Where Are We Going?
Uncategorized
Non-CME Credit Course
Are The New Changes in Congress an Answer for Inequity in Terms of Access to Molecular Testing and New Cancer Agents?
Uncategorized
Non-CME Credit Course
Cost of Medications: How to Make Them Affordable—Are We on the Right Direction?
Uncategorized
Non-CME Credit Course
Novel Targets: HER-2, NRG1, TROP2, CEACAM5 & HER-3
Uncategorized
Non-CME Credit Course
ALK & ROS-1: First Line & Mechanism of Resistance
Uncategorized
Non-CME Credit Course
EGFR PKI Resistance and K-RAS Mutations
Uncategorized
Non-CME Credit Course
Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs)
Uncategorized
Non-CME Credit Course
What After Immunotherapy Failure in First Line: Is There Hope?
Uncategorized
Non-CME Credit Course
Stage IIIA-B-C NSCLC: Does The PACIFIC Data Fit All-in-One?
Uncategorized
Non-CME Credit Course
Favoring The Adjuvant Concept
Uncategorized
Non-CME Credit Course
Favoring The Neoadjuvant Concept
Uncategorized
Non-CME Credit Course
Colorectal Cancer: Chemotherapy Combinations Targeted Therapy and Immunotherapy
Uncategorized
Non-CME Credit Course
Management of Melanoma: Early and Advanced Stages
Uncategorized
Non-CME Credit Course
Novel Advances in H&N and Thyroid Cancers
Uncategorized
Non-CME Credit Course
Cancer and Thrombosis: State-of-the-Art Management
Uncategorized
Non-CME Credit Course
Pain Management in Cancer Patients
Uncategorized
Non-CME Credit Course
Management of Metastatic Disease Using Interventional Radiology in 2023: Y90 SirSpheres and Other Procedures
Uncategorized
Non-CME Credit Course
Most Common Adverse Events of Checkpoint Inhibitors | Current Recommendations and Management
Uncategorized
Non-CME Credit Course
What Have We Learned from the Use Of Medical Marijuana: Myths and Facts
Uncategorized
Non-CME Credit Course
Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance
Uncategorized
Non-CME Credit Course
ALK, ROS-1, RET and MET
Uncategorized
Non-CME Credit Course
Head and Neck Cancers
Uncategorized
Non-CME Credit Course
Developing Targeted therapy for GU malignancies
Uncategorized
Non-CME Credit Course
Liver and Hepatic Malignancies: Times to Overcome Challenges
Uncategorized
Non-CME Credit Course
Targeted Therapy for Colon Cancer: What is New?
Uncategorized
Non-CME Credit Course
Developments in Gastric, and Esophageal Tumors
Uncategorized
Non-CME Credit Course
Immunotherapy for GU Malignancies and Exciting Developments
Uncategorized
Non-CME Credit Course
Immunotherapy for GYO Malignancies: Is There Still Time for Progress?
Uncategorized
Non-CME Credit Course
Establishing IO Management in Gastrointestinal Cancers
Uncategorized
Non-CME Credit Course
New Developments in Melanoma Early and Late Stage
Uncategorized
Non-CME Credit Course
Immunotherapy for Early-Stage Lung Cancer: Adjuvant and Neoadjuvant Approaches
Uncategorized
Non-CME Credit Course
Disparities in Breast Cancer Therapy Outcomes
Uncategorized
Non-CME Credit Course
Challenges in Her-2 Breast Cancer
Uncategorized
Non-CME Credit Course
Guidelines for Hormone Therapy in Breast Cancer
Uncategorized
Non-CME Credit Course
TNBC and Immunotherapy Developments in Breast Cancer
Uncategorized
Non-CME Credit Course
Liquid Biopsy
Uncategorized
Non-CME Credit Course
How Far Have We Gone with Biosimilars?
Uncategorized
Non-CME Credit Course
Latest Treatments in Triple Negative Breast Cancer
Uncategorized
Non-CME Credit Course
Updates on ER+ Breast Cancer
Uncategorized
Non-CME Credit Course
New Developments in HER2+ Breast
Uncategorized
Non-CME Credit Course
Role of Interventional Radiology in Oncology Care
Uncategorized
Non-CME Credit Course
Biosimilars Implementation in the United States: Where Opportunities Remain
Uncategorized
Non-CME Credit Course
SCLC Case
Uncategorized
Non-CME Credit Course
Stage IV KRAS Mutant Lung Cancer Case
Uncategorized
Non-CME Credit Course
EGFR-Mutated Lung Cancers
Uncategorized
Non-CME Credit Course
Immunotherapy
Uncategorized
Non-CME Credit Course
Targeted Therapy in Lung Cancer Updates
Uncategorized
Non-CME Credit Course
Lymphoma and CLL Update
Uncategorized
Non-CME Credit Course
Global Health and ASCO Update
Uncategorized
Non-CME Credit Course
GU Liquid Biopsy Updates
Uncategorized
Non-CME Credit Course
ASCO GI 2023 Updates
Uncategorized
Non-CME Credit Course
2023 Head and Neck Cancer Updates
Uncategorized
Non-CME Credit Course
Attracting, Recruiting and Retaining the Oncology Pharmacy Talent
Uncategorized
Non-CME Credit Course
Pharmacotherapy Updates in Malignant Hematology; Bispecifics and CAR-T Cell Therapies
Uncategorized
Non-CME Credit Course
Oncology Medication Safety; Building a Culture of Best Practices
Uncategorized
Non-CME Credit Course
Gene Therapies and Immunotherapy Updates in Solid Tumor Malignancies
Uncategorized
Non-CME Credit Course
Oncology Pharmacy Strategy Informed by Pharmacy Business Affairs Analytics
Uncategorized
Non-CME Credit Course
The Role of the Antimicrobial Stewardship Pharmacist in the Care of the Oncology Patient
Uncategorized
Non-CME Credit Course
Bone Health in Cancer Care
Uncategorized
Non-CME Credit Course
Oncology Pharmacy Operations Efficiency Journey
Uncategorized
Non-CME Credit Course
From the Young to the Grown-up; Pharmacotherapy Updates in Acute Lymphoblastic Leukemia (ALL)
Uncategorized
Non-CME Credit Course
Oncology Investigational Drug Services (IDS); Advancement of Quality and Efficiency Initiatives
Uncategorized
Non-CME Credit Course
Launching a Busulfan Kinetics Pharmacy Service; Real-World Case in Community Hospital Setting
Uncategorized
Non-CME Credit Course
Post Graduate Year II Oncology Residency Training; the South Florida Before, After, and Future Journey
Uncategorized
Non-CME Credit Course
White-Bagging Journey in Florida; Strategies to Protect Practice and Patients
Uncategorized
Non-CME Credit Course
Tips & Challenges in Neurology Research Budgeting
Uncategorized
Non-CME Credit Course
Radiating Salivary Glands in Patients with ALS for Sialorrhea
Uncategorized
Non-CME Credit Course
Brain Biorepositories
Uncategorized
Non-CME Credit Course
Neuro-palliative Care – “All About Dying”
Uncategorized
Non-CME Credit Course
Diagnosing ALS | Understanding ALS
Uncategorized
Non-CME Credit Course
National ALS Registry & Upcoming Research
Uncategorized
Non-CME Credit Course
Idiopathic Intracranial Hypertension: Updates on Imaging Findings, Pathophysiology, and Treatments
Uncategorized
Non-CME Credit Course
Changing Landscape of Therapeutic Development for Genetic ALS & All ALS
Uncategorized
Non-CME Credit Course
Pregnancy in MS and NMO
Uncategorized
Non-CME Credit Course
Caring for ALS: What I Wish I knew
Uncategorized
Non-CME Credit Course
Importance of Brain Biorepositories
Uncategorized
Non-CME Credit Course
Dysphasia in ALS
Uncategorized
Non-CME Credit Course
ALS Association – About Resources and Mission
Uncategorized
Non-CME Credit Course
Esophageal and Gastric Cancer New Developments
Uncategorized
Non-CME Credit Course
Prostate Cancer: From Hormonal Manipulation to Targeted Therapy
Uncategorized
Non-CME Credit Course
Neurological Complications and Management in the Era of Checkpoint Inhibitors
Uncategorized
Non-CME Credit Course
Burkitt Lymphoma
Uncategorized
Non-CME Credit Course
Double Hit Lymphomas
Uncategorized
Non-CME Credit Course
CNS Lymphomas
Uncategorized
Non-CME Credit Course
Current Standard of Therapies in CLL
Uncategorized
Non-CME Credit Course
New Therapies for Follicular Lymphoma
Uncategorized
Non-CME Credit Course
The Rule of Immunotherapy in the Treatment of Relapse Hodgkin Lymphoma
Uncategorized
Non-CME Credit Course
New Strategies for MCL
Uncategorized
Non-CME Credit Course
Marginal Zone Lymphomas
Uncategorized
Non-CME Credit Course
DLBCL: Current Therapeutic Approaches
Uncategorized
Non-CME Credit Course
PTCL: Evolving targeted therapies for mature T cell lymphoma
Uncategorized
Non-CME Credit Course
CTCL: Micosis Fungoides & Sezary Syndrome
Uncategorized
Non-CME Credit Course
Current Status of Cervical Cancer Screening
Uncategorized
Non-CME Credit Course
Role of ADCs in Gynecological Malignancies
Uncategorized
Non-CME Credit Course
Ovarian Cancer: Beyond Carboplatin and Paclitaxel
Uncategorized
Non-CME Credit Course
Endocrine Therapy for Advanced Breast Cancer: Current and Future Strategies
Uncategorized
Non-CME Credit Course
Endocrine Therapy and Targeted Agents for Early-Stage HR+ Breast Cancer
Uncategorized
Non-CME Credit Course
Antibody Drug Conjugates: New Agents and Optimal Sequencing
Uncategorized
Non-CME Credit Course
Immunotherapy for Breast Cancer: Updates and New Directions
Uncategorized
Non-CME Credit Course
Prostate Cancer: Role of PSMA PET and Accurately Defining “Neuroendocrine” Prostate
Uncategorized
Non-CME Credit Course
Role of Immunotherapy in HNC
Uncategorized
Non-CME Credit Course
Renal Cell Carcinoma (RCC): Current Approach to First Line Therapy and Beyond
Uncategorized
Non-CME Credit Course
Adjuvant and Neo-adjuvant Therapy for Lung Cancer
Uncategorized
Non-CME Credit Course
Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)
Uncategorized
Non-CME Credit Course
Approach to NSCLC With Targetable Mutations (EGFR, ALK and ROS-1)
Uncategorized
Non-CME Credit Course
Approach to NSCLC Without Targetable Mutations
Uncategorized
Non-CME Credit Course
Liquid Biopsy: Advances in the Last Decade and Future Directions
Uncategorized
Non-CME Credit Course
Melanoma as a Paradigm for the Future of Immunotherapy
Uncategorized
Non-CME Credit Course
Novel Immunotherapy Approaches in Hepatobiliary Malignancies
Uncategorized
Non-CME Credit Course
Pancreatic Cancer: Are We Finally Making Progress?
Uncategorized
Non-CME Credit Course
Current Status of CAR-T Therapy in Hematology
Uncategorized
Non-CME Credit Course
Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains
Uncategorized
Non-CME Credit Course
NTRK and Antibody Drug Conjugates in NSCLC
Uncategorized
Non-CME Credit Course
Brain Tumors and Sarcomas: New Developments
Uncategorized
Non-CME Credit Course
Biosimilars as Front Line Options for Cancer Care
Uncategorized
Non-CME Credit Course
2021 MCM | ISLB and MCM Symposia
Uncategorized
Non-CME Credit Course
Hematology Session III
Uncategorized
Non-CME Credit Course
Hematology Session II
Uncategorized
Non-CME Credit Course
Hematology Session I
Uncategorized
Non-CME Credit Course
Thoracic Oncology Session
Uncategorized
Non-CME Credit Course
Immunotherapy in Oncology Session II
Uncategorized
Non-CME Credit Course
Immunotherapy in Oncology Session I
Uncategorized
Non-CME Credit Course
Anticoagulation in Oncology: What’s New?
Uncategorized
Non-CME Credit Course
Liquid Biopsy: Indications in Oncology and Hematology
Uncategorized
Non-CME Credit Course
Palliative Care and the Importance of Advanced Care Planning
Uncategorized
Non-CME Credit Course
Integration of Biosimilars in Oncology Care
Uncategorized
Non-CME Credit Course
Novel Targeted Therapeutic Approaches for Breast Cancer
Uncategorized
Non-CME Credit Course
HER2+ Breast Cancer: De-escalating Therapy for Early Stage Disease and Optimal Sequencing for Metastatic Disease
Uncategorized
Non-CME Credit Course
New Directions in Adjuvant Endocrine Therapy
Uncategorized
Non-CME Credit Course
Immunotherapy in Breast Cancer: Recent Updates
Uncategorized
Non-CME Credit Course
Targeted Therapy for Metastatic HR+/HER2- Breast Cancer: CDK4/6 and PI3K
Uncategorized
Non-CME Credit Course
Impact of COVID-19 on Cancer Care
Uncategorized
Non-CME Credit Course
Integrating Biomarkers and Targeted Therapy into Colorectal Management
Uncategorized
Non-CME Credit Course
Gastric and Esophageal Cancers
Uncategorized
Non-CME Credit Course
Colon Cancer: Where Are We?
Uncategorized
Non-CME Credit Course
Emerging Combination in Sarcoma Immunotherapy
Uncategorized
Non-CME Credit Course
Bring New & Innovative Glioblastoma Treatments to the Clinical Practice
Uncategorized
Non-CME Credit Course
Natural Disasters: Infamy vs. Nature – What Lessons Can We Learn
Uncategorized
Non-CME Credit Course
T-cell NHL: Novel Treatments
Uncategorized
Non-CME Credit Course
Melanoma: What Is the Best Sequence of Therapy?
Uncategorized
Non-CME Credit Course
Updates in Metastatic Breast Cancer: Top News
Uncategorized
Non-CME Credit Course
Locally Advanced SqCCHN: Best Frontline for Unresectable Cancer and What Is Next at Relapse?
Uncategorized
Non-CME Credit Course
Novel Advances in Kidney and Bladder Cancers
Uncategorized
Non-CME Credit Course
Immunotherapy in Metastatic NSCLC: Frontline and What’s After Immunotherapy Failure
Uncategorized
Non-CME Credit Course
Multiple Myeloma: What Are the New Challenges?
Uncategorized
Non-CME Credit Course
B-cell NHL: Highlights from ASCO/EHA
Uncategorized
Non-CME Credit Course
Developmental Therapeutics and Novel Agents
Uncategorized
Non-CME Credit Course
Targeted Therapy in Non-Squamous NSCLC: Where Are We and What Is Coming Up?
Uncategorized
Non-CME Credit Course
Ovarian and Uterine Cancer: Novel Approaches
Uncategorized
Non-CME Credit Course
Liquid Biopsy: How Are We Utilizing It and Where Is This Technology Moving To?
Uncategorized
Non-CME Credit Course
Colorectal cancers: Where Are We Moving?
Uncategorized
Non-CME Credit Course
Gastrointestinal Cancer
Uncategorized
Non-CME Credit Course
New Developments in Cancer Research
Uncategorized
Non-CME Credit Course
Breast Cancer
Uncategorized
Non-CME Credit Course
Solid Tumor Oncology
Uncategorized
Non-CME Credit Course
Hematologic Malignancies
Uncategorized
Non-CME Credit Course
Genitourinary Cancer
Uncategorized
Non-CME Credit Course
Lung Cancer
Uncategorized
Non-CME Credit Course
Cancer Immunotherapy
Uncategorized
Non-CME Credit Course
Challenging Cases in Oncology
Uncategorized
Non-CME Credit Course
Modern Clinical Trial Design, Pharmacology and Drug Development
Uncategorized
Non-CME Credit Course
Management of Trigeminal Nerve Injuries
Uncategorized
Non-CME Credit Course
Diagnosis and Management of Dentin Hypersensitivity
Uncategorized
Non-CME Credit Course
Delayed Replantation of an Avulsed Maxillary Lateral Incisor: A Case Report
Uncategorized
Non-CME Credit Course
Massive Maxillary Tumors: Challenges and Considerations
Uncategorized
Non-CME Credit Course
An Overview of the Cancer Workup:From Biopsy to Surgery
Uncategorized
Non-CME Credit Course
The Future of Anesthesia in OMFS: The Outlook
Uncategorized
Non-CME Credit Course
Surgical Progression of a Maxillofacial Trauma Patient Sustaining an Industrial Accident
Uncategorized
Non-CME Credit Course
Advantages and Disadvantages of VSP in Current Residency Training
Uncategorized
Non-CME Credit Course
Optimal Therapeutic Strategies for Chronic Lymphocytic Leukemia
Uncategorized
Non-CME Credit Course
What's New in Multiple Myeloma?
Uncategorized
Non-CME Credit Course
Cancer-related Bleeding and Thrombosis
Uncategorized
Non-CME Credit Course
State of the Art in Acute Leukemias
Uncategorized
Non-CME Credit Course
Late Recurrences in ER Positive Breast Cancer: The Next Frontier?
Uncategorized
Non-CME Credit Course
Liquid Biopsies in Breast Cancer: Fact, Fiction, and Promise
Uncategorized
Non-CME Credit Course
Updates in Sarcoma Therapies
Uncategorized
Non-CME Credit Course
State of the Art in Gynecologic Oncology
Uncategorized
Non-CME Credit Course
Updates in Immunotherapy & Targeted Therapy in Gastrointestinal Cancers
Uncategorized
Non-CME Credit Course
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from February 2020
Uncategorized
Non-CME Credit Course
Case Presentation - Lung - Immunotherapy Toxicity Case, How to Manage and Whether to Permanently Stop or Not
Uncategorized
Non-CME Credit Course
Immunotherapy selection in mRCC
Uncategorized
Non-CME Credit Course
Small Cell Lung Cancer - 2 New IO Regimens as Standard of Care
Uncategorized
Non-CME Credit Course
Triple-negative and Hereditary Breast Cancer
Uncategorized
Non-CME Credit Course
A Case Presentation in Metastatic Breast Cancer - Opportunities for Immunotherapy
Uncategorized
Non-CME Credit Course
HER+, ER+, San Antonio Update
Uncategorized
Non-CME Credit Course
Non-Clear Cell RCC - Emerging Approaches
Uncategorized
Non-CME Credit Course
Targeted Therapy
Uncategorized
Non-CME Credit Course
Promising Immunotherapy for Melanoma
Uncategorized
Non-CME Credit Course
Case Presentation - Breast
Uncategorized
Non-CME Credit Course
Lung Cancer Immunotheraphy Case Presentation
Uncategorized
Non-CME Credit Course
Case Presentation - GU
Uncategorized
Non-CME Credit Course
Lung Targeted Therapies in NSCLC - BRAF, RET, MET and NTRK
Uncategorized
Non-CME Credit Course
Novel Therapeutic Strategies in Acute Myeloid Leukemia Our Cup Runneth Over
Uncategorized
Non-CME Credit Course
Moving the Needle on Bladder Cancer Survival - a Urologist’s Perspective
Uncategorized
Non-CME Credit Course
Current State of Lung Cancer Screening
Uncategorized
Non-CME Credit Course
Advances in Oncology 2019: Breast Cancer Update
Uncategorized
Non-CME Credit Course
Translating Clinical Trials' Results into Clinical Practice
Uncategorized
Non-CME Credit Course
Optimal Therapies in Genitourinary Cancers
Uncategorized
Non-CME Credit Course
Optimal Therapeutic Strategies in GI Cancers
Uncategorized
Non-CME Credit Course
Challenging Cases in Breast Cancer
Uncategorized
Non-CME Credit Course
T-Cell Lymphomas - New Therapeutic Approaches
Uncategorized
Non-CME Credit Course
Sequencing drugs in mCRPC
Uncategorized
Non-CME Credit Course
Neural Stem Cell Based Anti-Cancer Gene Therapy for Gliomas
Uncategorized
Non-CME Credit Course
DLBCL: The Latest and Greatest
Uncategorized
Non-CME Credit Course
HER2+ Breast Cancer State of the Art
Uncategorized
Non-CME Credit Course
How I Treat Metastatic Urothelial Cancer after IO Therapy Fails
Uncategorized
Non-CME Credit Course
Urothelial Cancer New Strategies
Uncategorized
Non-CME Credit Course
Immunotherapy for Advanced Non-Small Cell Lung Cancer
Uncategorized
Non-CME Credit Course
Advances in Immunotherapy
Uncategorized
Non-CME Credit Course
Acute Lymphoblastic Leukemia Latest Advances
Uncategorized
Non-CME Credit Course
Colorectal Cancer State of the Science
Uncategorized
Non-CME Credit Course
New Immunotherapeutic Strategies Checkpoint Inhibitors and Beyond
Uncategorized
Non-CME Credit Course
Targeted Therapies in Metastatic RCC Monotherapy versus Combination Therapy
Uncategorized
Non-CME Credit Course
Innovative Early Phase Clinical Trial Designs
Uncategorized
Non-CME Credit Course
Contact Us
